IDXX

IDEXX is the global leader in companion-animal in-clinic diagnostics, reference labs, and practice software, with a sticky “razor/razorblade” model where instrument placements drive recurring consumables and lab volume. Its scale, menu breadth, and workflow integration create high switching costs for clinics, helping it hold pricing power even when U.S. vet visit trends soften. Management is also leaning into innovation (for example, IDEXX inVue Dx placements and expanded cancer testing), which can reinforce the moat if adoption stays strong.

Financially, IDEXX exited 2025 with $4.304B of revenue (10% growth) and operating margin of 31.6%, plus about $1.1B of free cash flow (roughly 100% of net income), supporting ongoing buybacks (about $1.2B repurchased in 2025). The company guided 2026 revenue to $4.632B–$4.720B and EPS to $14.29–$14.80, implying continued double-digit earnings growth but not a re-acceleration. Valuation remains demanding at roughly ~50x earnings, which leaves limited room for execution missteps.

Over the next 12 months, the stock likely follows whether IDEXX can sustain CAG diagnostic recurring growth despite choppy clinical visit levels and whether new platforms (notably inVue Dx) translate into higher utilization and mix. The May 5, 2026 earnings report is a near-term catalyst for visit commentary, pricing, and placement momentum. Key risks are a further slowdown in clinic traffic, a faster competitive response, or multiple compression if growth merely matches guidance.

Recommendation: HOLD. IDEXX combines exceptional business quality and cash generation with clear 2026 earnings visibility, but the current premium valuation makes upside more dependent on upside-to-guidance execution than on steady compounding alone.